FAKTOR-ZERTIFIKAT - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 07:00:11 2024-06-14 EDT | ||
| 5.47 EUR / 5.57 EUR | +3.56% |
|
| Current month | -19.85% | ||
| 1 month | -38.81% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 5.5 | +3.19% |
| 24-06-13 | 5.33 | -2.02% |
| 24-06-12 | 5.44 | +4.82% |
| 24-06-11 | 5.19 | +1.96% |
| 24-06-10 | 5.09 | +0.59% |
Delayed Quote Börse Stuttgart
Last update June 14, 2024 at 04:51 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JK2J2A |
| ISIN | DE000JK2J2A9 |
| Date issued | 2024-02-23 |
| Strike | 598.8 $ |
| Maturity | Unlimited |
| Parity | 21.59 : 1 |
| Emission price | 10.08 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.13 € |
|---|---|
| Lowest since issue | 4.98 € |
| Spread | 0.1 € |
| Spread % | 1.80% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
479
USD
Average target price
463.4
USD
Spread / Average Target
-3.26%
- Stock Market
- Certificates
- Certificat
